Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCM-WINE: Yi-Qi-Qing-Jie Formula in High-Risk IgA Nephropathy
NCT03418779Phase 3Active, not recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- Jul 2019
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) (2 arms), sponsored by Guang'anmen Hospital. Primary endpoints: First occurrence of 40% decrease in eGFR from baseline at 3 years, First occurrence of progression to continuous renal replacement at 3 years and 1 more. Started Jul 2019; status: active, not recruiting.
02
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT03418779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03418779.